Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep;13(3):203-8.
doi: 10.1016/j.aju.2015.07.003. Epub 2015 Aug 5.

The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection

Kirill V Kosilov  1 , Sergay A Loparev  2 , Marina A Ivanovskaya  3 , Liliya V Kosilova  4
Affiliations

The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection

Kirill V Kosilov et al. Arab J Urol. 2015 Sep.

Abstract

Objective: To determine the efficacy and safety of solifenacin for correcting the residual symptoms of an overactive bladder (OAB) in patients who were treated for a urinary tract infection (UTI).

Patients and methods: Using random sampling, 524 patients aged >60 years were selected (347 women, 66.2%, and 177 men, 33.8%). They denied the presence of any symptoms of detrusor overactivity in their medical history, but had a diagnosis of a UTI. At least 1 month after the end of treatment and a laboratory confirmation of the absence of infection, each patient completed an OAB-Awareness Tool questionnaire (OAB signs, total score 8 points), and a noninvasive examination of urinary function (uroflowmetry). Each day patients in group A took solifenacin 10 mg and those in group B took 5 mg, with patients in group C being given a placebo.

Results: During the study 58.8% of patients had symptoms of an OAB at 1 month after the end of the treatment for a UTI, and normal laboratory markers. During treatment with the standard and higher dose of solifenacin, within 8 weeks most variables of the condition of the lower urinary tract reached a normal state or improved.

Conclusion: Patients aged >60 years who had been treated for a UTI have a high risk of developing symptoms of an OAB. Solifenacin in standard doses is an efficient and safe means of managing overactive detrusor symptoms after a UTI.

Keywords: Elderly men; IE, incontinence episodes; LUT, lower urinary tract; OAB, overactive bladder; OAB-AT, OAB Awareness Tool (questionnaire); Overactive bladder; Solifenacin; UE, urgency episodes; Urinary tract infection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of the groups, examinations and treatment. UF, uroflowmetry.
Figure 2
Figure 2
Changes in the number of UE (A) and IE (B) after taking solifenacin.
See this image and copyright information in PMC

Comment in

References

    1. Rowe T.A., Juthani-Mehta M. Urinary tract infection in older adults. Aging Health. 2013;9(5) - PMC - PubMed
    1. Eriksson I., Gustafson Y., Fagerström L., Olofsson B. Do urinary tract infections affect morale among very old women? Health Qual Life Outcomes. 2010;8:73. - PMC - PubMed
    1. Matthews S.J., Lancaster J.W. Urinary tract infections in the elderly population. Am J Geriatr Pharmacother. 2011;9:286–309. - PubMed
    1. Rowe T.A., Juthani-Mehta M. Diagnosis and management of urinary tract infection in older adults. Infect Dis Clin North Am. 2014;28:75–89. - PMC - PubMed
    1. Mody L., Juthani-Mehta M. Urinary tract infections in older women: a clinical review. JAMA. 2014;311:844–854. - PMC - PubMed

LinkOut - more resources